LTBR and rheumatoid arthritis: Our findings suggest that targeting lymphotoxin signaling, LTα3-TNFR interactions and LTα1β2-LTβR interactions, with pateclizumab on background DMARDs is insufficient to produce a significant reduction in the inflammatory process in RA or to provide superior efficacy over adalimumab, an anti-TNF agent that is commonly used for DMARD-IR RA patients.